Denny Won

Cooley advised the underwriters of Viking Therapeutics – a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders – on its $632.5 million public offering of common stock.

Cooley advised the underwriters in Sagimet Biosciences’ $112.5 million follow-on offering. Goldman Sachs, TD Cowen and Leerink Partners acted as joint book-running managers for the offering. JMP Securities is acting as lead manager for the offering. Sagimet Biosciences’ is a clinical-stage biopharmaceutical company developing novel fatty acid synthase inhibitors designed to target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid palmitate. Partners John McKenna, Natalie Karam and Denny Won led the Cooley team.

Cooley advised Abivax, a clinical-stage biotech company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering.

Cooley advised the underwriters in Vistagen Therapeutics’ $100 million follow-on offering of common stock, pre-funded warrants, and two tranches of common stock warrants, with Jefferies, Stifel and William Blair acting as lead book-running managers. Vistagen Therapeutics is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system disorders. Partners Denny Won, Charlie Kim and Courtney Tygesson led the Cooley team.